SCHEMBL10074427

SCHEMBL10074427

CCC1CCC(=O)N(O)C1=O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.33
MMP2 P08253 2/20 0.31
MMP9 P14780 2/20 0.31
MMP12 P39900 2/20 0.31
MMP14 P50281 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228528 0.79 CYP2C19 (0.44) CYP2C19
SCHEMBL22450066 0.76
SCHEMBL9518366 0.76
SCHEMBL13594982 0.73 MME (0.33) CYP2C19
Phosphoric Acid SCHEMBL29182602 0.73 ALDH1A1 (0.33)
SCHEMBL10049352 0.72 PIK3CD (0.34) MMP2MMP9MMP12MMP14
SCHEMBL1524639 0.71
SCHEMBL30642653 0.68 MT-CO2 (0.52)
SCHEMBL8222968 0.68 DPP4 (0.33) MMP2MMP9MMP12MMP14
SCHEMBL15264476 0.68 KMT2A (0.33) CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093386-B2 Thioaryl substituted inhibitors of zinc proteases and their use BRACCO IMAGING S.P.A (IT) 2012-01-10 US disclosed
US-20090239829-A1 THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE BRACCO IMAGING SPA (IT) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239829-A1 THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE SERPINB1, ZFX, MMP2 CYP2C19 353/4885MMP2 3/4885MMP9 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.